Fast skeletal muscle troponin activator CK-2066260 mitigates skeletal muscle weakness independently of the underlying cause

Arthur J. Cheng¹, Jennifer Ström¹, Darren T. Hwee³, Fady I. Malik³ & Håkan Westerblad¹* (✉)

¹Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, ²School of Kinesiology and Health Science, Faculty of Health, York University, Toronto, Canada, ³Research and Early Development, Cytokinetics, Inc., South San Francisco, CA, USA

Abstract

Background Muscle weakness is a common symptom in numerous diseases and a regularly occurring problem associated with ageing. Prolonged low-frequency force depression (PLFFD) is a form of exercise-induced skeletal muscle weakness observed after exercise. Three different intramuscular mechanisms underlying PLFFD have been identified: decreased sarcoplasmic reticulum Ca²⁺ release, decreased myofibrillar Ca²⁺ sensitivity, and myofibrillar dysfunction. We here used these three forms of PLFFD as models to study the effectiveness of a fast skeletal muscle troponin activator, CK-2066260, to mitigate muscle weakness.

Methods Experiments were performed on intact single muscle fibres or fibre bundles from mouse flexor digitorum brevis, which were stimulated with electrical current pulses, while force and the free cytosolic [Ca²⁺] ([Ca²⁺]) were measured. PLFFD was induced by three different stimulation protocols: (i) repeated isometric contractions at low intensity (350 ms tetani given every 5 s for 100 contractions); (ii) repeated isometric contractions at high intensity (250 ms tetani given every 0.5 s for 300 contractions); and (iii) repeated eccentric contractions (350 ms tetani with 20% length increase given every 20 s for 10 contractions). The extent and cause of PLFFD were assessed by comparing the force–[Ca²⁺] relationship at low (30 Hz) and high (120 Hz) stimulation frequencies before (control) and 30 min after induction of PLFFD, and after an additional 5 min of rest in the presence of CK-2066260 (10 μM).

Results Prolonged low-frequency force depression following low-intensity and high-intensity fatiguing contractions was predominantly due to decreased sarcoplasmic reticulum Ca²⁺ release and decreased myofibrillar Ca²⁺ sensitivity, respectively. CK-2066260 exposure resulted in marked increases in 30 Hz force from 52 ± 16% to 151 ± 13% and from 6 ± 4% to 98 ± 40% of controls with low-intensity and high-intensity contractions, respectively. Following repeated eccentric contractions, PLFFD was mainly due to myofibrillar dysfunction, and it was not fully reversed by CK-2066260 with 30 Hz force increasing from 48 ± 8% to 76 ± 6% of the control.

Conclusions The fast skeletal muscle troponin activator CK-2066260 effectively mitigates muscle weakness, especially when it is caused by impaired activation of the myofibrillar contractile machinery due to either decreased sarcoplasmic reticulum Ca²⁺ release or reduced myofibrillar Ca²⁺ sensitivity.

Keywords Muscle weakness; Troponin activator; Free cytosolic [Ca²⁺]; Prolonged low-frequency force depression; Muscle fatigue.

© 2020 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Introduction

Muscle weakness is a common symptom in numerous diseases, and it is also a regularly occurring problem associated with ageing. Reduced muscle strength can have a large negative impact on everyday activities and quality of life, and population studies reveal an association between reduced muscle strength and mortality. Muscle weakness is generally due to a combination of atrophy (i.e. decreased muscle cross-sectional area) and impaired muscle quality (i.e. a reduced ability of muscle fibres to generate force). Intracellularly, impaired muscle quality can be due to decreased myofibrillar force-generating capacity and/or impaired activation of the myofibrillar contractile machinery, which in turn can be caused by decreased sarcoplasmic reticulum (SR) Ca\(^{2+}\) release and/or reduced myofibrillar Ca\(^{2+}\) sensitivity. Prolonged muscle weakness related to reductions in myofibrillar force-generating capacity and Ca\(^{2+}\) sensitivity due to a preferential loss of myosin has been observed in mechanically ventilated intensive care unit patients and patients with cancer cachexia. Similarly, impaired force-generating capacity combined with decreased myofibrillar Ca\(^{2+}\) sensitivity has been observed in animal models of rheumatoid arthritis, but in this case, actin, rather than myosin, appears preferentially affected. Moreover, muscle weakness has been linked to decreased SR Ca\(^{2+}\) release in ageing as well as in several pathological conditions, including heart failure, muscular dystrophy, mitochondrial myopathy, and bone cancer.

Prolonged low-frequency force depression (PLFFD) is typically described as a long-lasting muscle weakness that persists in the recovery period after endurance-type exercise. This muscle weakness is most evident during submaximal contractions in which a given frequency of motor unit activity gives a lower than expected contractile force. Because PLFFD is readily observed with direct electrical muscle stimulation in humans after fatiguing exercise and in isolated fatigued mammalian skeletal muscle, intramuscular mechanisms have been implicated as major contributors to PLFFD. A phenomenon similar to PLFFD has been found after resistance-type exercise involving high-force eccentric contractions. PLFFD is generally attributed to decreased SR Ca\(^{2+}\) release and/or reduced myofibrillar Ca\(^{2+}\) sensitivity after isometric contractions, whereas reduced myofibrillar force-generating capacity may contribute to PLFFD after eccentric contractions. Thus, PLFFD involves the same cellular mechanisms as those causing muscle weakness in several disease conditions (see earlier).

Fast skeletal muscle troponin activators (FSTAs) are small molecules that decrease the off-rate of Ca\(^{2+}\) from troponin C, resulting in amplified force for a given submaximal myoplasmic free [Ca\(^{2+}\)] ([Ca\(^{2+}\)]\(_i\)). Motor units generally fire at submaximal frequencies during voluntary contractions, and FSTAs are most effective during submaximal contractions where even minor increases in the [Ca\(^{2+}\)]-dependent activation of the contractile machinery result in large force increases due to the steep force–[Ca\(^{2+}\)] relationship. Indeed, the FSTA CK-2066260 effectively increased force when muscle fibres had entered the steep part of the force–[Ca\(^{2+}\)] relationship during fatigue induced by repeated tetanic contractions. Thus, FSTAs can prove effective in amplifying submaximal force, especially under conditions with reduced submaximal force, such as the muscle weakness accompanying several pathological conditions. The purpose of this study is to use PLFFD induced by different exercise tasks, and hence caused by different mechanisms, as a tool to assess the effectiveness of FSTAs to combat muscle weakness in various pathological conditions. Our results show that the FSTA CK-2066260 effectively mitigates muscle weakness due to decreased myofibrillar activation due to either decreased SR Ca\(^{2+}\) release or reduced myofibrillar Ca\(^{2+}\) sensitivity.

Methods

Mice

All animal experiments were performed at Karolinska Institutet in the Department of Physiology and Pharmacology, and all animal experimental procedures were approved by the Stockholm North local ethical committee (N19/15) and complied with the Swedish Welfare Ordinance, and applicable regulations and recommendations from Swedish authorities. Eight-week-old female C57BL6jRj mice (Janvier Labs, Le Genest-Saint-Ilie, France) were acclimated for at least 7 days before being used for experiments. Mice were housed in cages with a 12/12 h light/dark cycle and were provided with food and water ad libitum. A total of 13 mice were used for experiments.

Mice were killed by rapid cervical dislocation, and whole flexor digitorum brevis muscles (FDBs) were removed. Intact single muscle fibres were mechanically isolated with tendons attached, as described elsewhere. This intact single fibre preparation is appropriate for prolonged experiments as there is no, or very little, rundown in force production during procedures lasting several hours. For all experiments, fibres were superfused at room temperature (~26°C) using a constant rate superfusion system without recirculation, including the periods when fibres were exposed to CK-2066260. Thus, fibres were continuously superfused with fresh oxygenated Tyrode’s solution (95% O\(_2\) and 5% CO\(_2\)) of the following composition (in mM): 121 NaCl, 5.0 KCl, 1.8 CaCl\(_2\), 0.5 MgCl\(_2\), 0.4 NaH\(_2\)PO\(_4\), 24.0 NaHCO\(_3\), 0.1 EDTA, and 5.5 glucose. For the isometric contractions, single fibres were mounted on hooks between an Akers 801 force transducer (Kronex Technologies, Oakland, CA, USA) and an adjustable holder that allowed muscle length to be adjusted to the optimum length of force production. For the lengthening contractions, single fibres, or small bundles of 5–10 fibres, were
mounted on hooks between an Aurora Scientific force transducer (Model 1500A, Aurora Scientific, Aurora, Ontario, Canada) and a motor lever that controlled the lengthening contractions (Model 315C, Aurora Scientific). The smallest and largest fibre diameters were measured at optimal length using a camera mounted to the inverted microscope, and these diameters were used to calculate the cross-sectional area assuming that the fibre had an elliptical cross section. [Ca\(^{2+}\)], measurements were performed by injecting fibres with indo-1 pentapotassium salt or loading them with the membrane permeable AM dye (Thermo Fisher Scientific, Gothenburg, Sweden). Indo-1 is a ratiometric high-affinity calcium indicator excited at 346 nm wavelength using a Xenon light source and monochromator (Horiba Scientific, Photon Technology International, London, Canada) with light emitted at 405 and 495 nm recorded by two photomultipliers (Horiba Scientific, Photon Technology International) and calculated as a ratio. Data were acquired at a 100 Hz sampling rate. Indo-1 fluorescence ratios were converted into [Ca\(^{2+}\)]\(_i\) using an in vivo calibration as described previously.\(^{34}\) During each contraction, [Ca\(^{2+}\)]\(_i\) was measured as the mean over the entire 350 ms stimulation period.

### Stimulation protocols

Supramaximal current pulses with a duration of 0.5 ms were used to stimulate muscle fibres to contract. Fibres were exposed to one of the three stimulation protocols: (i) low-intensity isometric contractions, (ii) high-intensity isometric contractions, and (iii) eccentric contractions (see Supporting Information, Figure S1). To determine the baseline force–[Ca\(^{2+}\)]\(_i\) relationship for each fibre at the start of the experiment, fibres in the two isometric groups were initially stimulated to produce contractions at 15–150 Hz (350 ms duration) at 1 min intervals, and force and [Ca\(^{2+}\)]\(_i\), were recorded. After 5 min of rest, fatiguing stimulation commenced. Fibres in the low-intensity group were given sub-maximal 50 Hz tetani of 350 ms duration every 5 s for 100 contractions.\(^{31}\) In the high-intensity group, fibres were exposed to six sets of 30 s contraction bouts consisting of 250 ms, 100 Hz contractions given at 500 ms interval with 4.5 min rest between bouts.\(^{25}\) After 30 min recovery, fibres were stimulated at low frequency (30 Hz) and at high frequency (120 Hz) to determine the extent of PLFFD. Thereafter, fibres were treated for 5 min with CK-2066260 (10 μM) and then stimulated again at 30 and 120 Hz to determine the extent to which CK-2066260 counteracted PLFFD. No control experiments were performed to assess a potential increase in force between 30 and 35 min of recovery without exposure to CK-2066260 because previous studies show that fibres are in a stable state of PLFFD during this time period, which means that no or very minor changes in force would be expected.\(^{21,35}\)

Flexor digitorum brevis muscle single fibres or small fibre bundles were exposed to repeated eccentric fibres or small fibre bundles were exposed to repeated eccentric contractions after adjusting to optimal length for force production. The baseline isometric force at 30 and 120 Hz was measured during 350 ms contractions with 1 min of rest between contractions. Thereafter, the repeated lengthening contraction protocol commenced with 100 Hz tetani (350 ms duration) given once every 20 s for a total of 10 contractions. A 20% ramp length change was performed during the final 150 ms of each contraction.\(^{27}\) Finally, force was measured during 30 and 120 Hz isometric tetani after 30 min recovery in standard Tyrode and after additional 5 min in the presence of CK-2066260 (10 μM). [Ca\(^{2+}\)], was not measured in the eccentric contraction experiments because we recently showed that tetanic [Ca\(^{2+}\)], was only marginally affected by a much more severe protocol with 100 repeated eccentric contractions.\(^{27}\)

### Statistics

Statistical evaluation employed repeated measures analysis of variance using GraphPad Prism 8.1.2 software (GraphPad, San Diego, CA, USA). Post hoc analysis was performed using either Tukey’s or Dunnett’s test. Data are presented as mean ± standard error of the mean. Statistically significant differences were determined at \(P < 0.05\).

### Results

#### Low-intensity isometric contractions

The low-intensity isometric contractions protocol resulted in marked fatigue with the force in the last of the 100 tetani being reduced to 47 ± 4% of the force in the first tetanus (\(n = 7\)). This force decrease was associated with a progressive decline in mean tetanic [Ca\(^{2+}\)], to 76 ± 13% of the initial value (Figure 1A). At 30 min post-fatigue, the extent of PLFFD was assessed by stimulating at low (30 Hz) and high (120 Hz) frequencies with PLFFD typically exemplified by a more pronounced force depression at the lower stimulation frequency. Indeed, PLFFD was induced by the low-intensity fatigue protocol with decreased 30 Hz force and tetanic [Ca\(^{2+}\)], whereas there was no significant reduction in 120 Hz force (Figures 1B and 2A). The major cause of PLFFD following low-intensity contractions was reduced SR Ca\(^{2+}\) release; although both 30 Hz force and [Ca\(^{2+}\)], at 30 min recovery were decreased, the relation between them still lies near the unfatigued force–[Ca\(^{2+}\)], relationship (Figure 2B). We also observed a decrease in 120 Hz tetanic [Ca\(^{2+}\)], (Figures 1B and 2A), but it did not cause a force reduction because tetanic [Ca\(^{2+}\)], was large enough to reach the plateau of the force–[Ca\(^{2+}\)], relationship where changes in [Ca\(^{2+}\)], have little impact on force production (Figure 2B). PLFFD was fully reversed following 5 min superfusion with
CK-2066260. In fact, 30 Hz force in the presence of CK-2066260 was larger than at baseline (PRE), and this occurred without any significant alteration in 
\([\text{Ca}^{2+}]_i\) (Figures 1B and 2). On the other hand, 120 Hz force and 
\([\text{Ca}^{2+}]_i\) were not affected by CK-2066260 treatment. Thus, PLFFD following low-intensity stimulation was caused by decreased SR Ca\(^{2+}\) release and CK-2066260 reversed PLFFD by increasing myofibrillar Ca\(^{2+}\) sensitivity.

**High-intensity isometric contractions**

Next, we used a stimulation paradigm that mimicked high-intensity exercise in humans involving six sets of high-frequency contractions given at a 50% duty cycle for 30 s.\(^{27}\) The typical 
\([\text{Ca}^{2+}]_i\) and force records in Figure 3A show that severe fatigue developed during each set of contractions and that partial recovery took place during the resting period between sets. A marked PLFFD was observed 30 min after cessation of these high-intensity contractions with 30 Hz force being decreased to <10% of the unfatigued values (Figures 3B, 4A, and 4B). We also observed a decrease in 
\([\text{Ca}^{2+}]_i\) during contractions, but the force reduction was much larger than what could be explained by the decrease in 
\([\text{Ca}^{2+}]_i\). This means that in addition to decreased SR Ca\(^{2+}\) release, the high-intensity stimulation also resulted in a marked decrease in myofibrillar Ca\(^{2+}\) sensitivity, which was manifested as a substantial rightward shift in the force–\([\text{Ca}^{2+}]_i\) relationship.
Nevertheless, 5 min exposure to CK-2066260 reversed PLFFD, and this occurred without any significant effect on tetanic $\left[\text{Ca}^{2+}\right]_{i}$ (Figures 3B and 4).

**Eccentric contractions**

Prolonged low-frequency force depression can be observed following repeated eccentric contractions with myofibrillar damage as a dominant cause of PLFFD. In a final set of experiments, FDB fibres or small fibre bundles were exposed to eccentric 100 Hz tetani at long (20 s) rest periods between contractions. These long rest periods were applied in order to minimize fatigue development due to metabolic alterations while allowing for induction of impaired myofibrillar function with the repeated lengthening contractions. Typical force traces from the first and last (10th) contractions show that the repeated eccentric contractions resulted in

**FIGURE 2** CK-2066260 reverses prolonged low-frequency force depression after low-intensity contractions. (A) Mean values of 30 and 120 Hz tetanic $\left[\text{Ca}^{2+}\right]_{i}$ and force elicited in the unfatigued state (PRE), at 30 min of recovery (R30), and after an additional 5 min superfusion with 10 μM of CK-2066260 (CK260). (B) Mean force–$\left[\text{Ca}^{2+}\right]_{i}$ relationship obtained from 15 to 150 Hz stimulations in the unfatigued state (PRE), and 30 and 120 Hz force and tetanic $\left[\text{Ca}^{2+}\right]_{i}$ elicited at 30 min of recovery (R30), and after 5 min superfusion with 10 μM CK-2066260. Data shown as mean ± standard error of the mean ($n = 5$). *Significantly different from PRE at $P < 0.05$. †Significant main effect with depressed 120 Hz tetanic $\left[\text{Ca}^{2+}\right]_{i}$ during prolonged low-frequency force depression at $P < 0.05$, whereas the post hoc test did not show any significant difference between the individual groups.
~50% decrease in isometric force (i.e. before the start of lengthening) and peak force during the eccentric phase (Figure 5A). After 30 min of recovery, PLFFD was evident with a greater relative reduction in 30 Hz than in 120 Hz tetanic force (Figure 5B and 5C). Five minute superfusion with CK-2066260 partially recovered 30 Hz force, whereas 120 Hz force was not improved. Thus, while CK-2066260 proved beneficial in partially reversing PLFFD following repeated eccentric contractions, it could not compensate for the impaired cross-bridge force-generating capacity manifested as decreased near-maximal 120 Hz force (Figure 5C).

**Discussion**

Skeletal muscle weakness, premature fatigue development, and exercise intolerance are important features in numerous pathological conditions. These muscle deficiencies can also develop as a consequence of a lifestyle with limited physical activity, as part of the ageing process, or in mechanically ventilated intensive care unit patients. Here, we used PLFFD induced by three types of exercise as models of muscle weakness with different underlying mechanisms. The results show that the FSTA CK-2066260 fully reversed...
muscle weakness following low-intensity and high-intensity exercise, while it was only partially effective in reversing the weakness induced by damaging eccentric contractions. Skeletal muscle fatigue induced by low-intensity to moderate-intensity endurance-type exercise has been related to intramuscular glycogen depletion and impaired SR Ca\textsuperscript{2+} release.\textsuperscript{44–48} Thus, the recovery of SR Ca\textsuperscript{2+} release and force following prolonged endurance exercise will largely depend on the rate of glycogen re-synthesis,\textsuperscript{35} which is slow, with up to 24 h potentially required for glycogen to be fully restored.\textsuperscript{49,50} The low-intensity stimulation protocol used in the present study has been shown to cause glycogen depletion and decreased SR Ca\textsuperscript{2+} release.\textsuperscript{51} Accordingly, PLFFD after the low-intensity stimulation can be fully ascribed to decreased [Ca\textsuperscript{2+}], during contractions (see Figure 2). The FSTA CK-2066260 reversed PLFFD by increasing myofibrillar Ca\textsuperscript{2+} sensitivity, which fully compensated for the decreased SR Ca\textsuperscript{2+} release. In fact, submaximal forces in the presence of the FSTA were even larger than in the unfatigued state. Translated to the in vivo situation, this means that the same

FIGURE 4 CK-2066260 reverses the severe prolonged low-frequency force depression induced by high-intensity contractions. (A) Mean values of 30 and 120 Hz tetanic [Ca\textsuperscript{2+}], and force elicited in the unfatigued state (PRE), at 30 min of recovery (R30), and after an additional 5 min superfusion with 10 μM CK-2066260 (CK260). (B) Mean force–[Ca\textsuperscript{2+}] relationship obtained from 15 to 150 Hz stimulations in the unfatigued state (PRE), and mean 30 and 120 Hz force–[Ca\textsuperscript{2+}] values obtained at 30 min of recovery (R30), and after an additional 5 min superfusion with 10 μM CK-2066260. CK-2066260 fully recovers force by markedly increasing myofibrillar Ca\textsuperscript{2+} sensitivity, while tetanic [Ca\textsuperscript{2+}], remains unaffected. Data shown as mean ± standard error of the mean (n = 5). *Significantly different from value at PRE at P < 0.05.
Muscular activity can be performed at a decreased neuronal activation (i.e., fewer motor units activated and/or reduced frequency of action potentials in active motor units), which will facilitate physical activities in people suffering from muscle weakness. Moreover, in the presence of the FSTA, less SR Ca\(^{2+}\) release is required to produce the same force, which might further improve the performance during endurance-type activities by reducing the energy consumed by the ATP-driven SR Ca\(^{2+}\) reuptake. A potential concern with FSTA treatment is that the rate of force relaxation will decrease, which might impair performance during activities requiring rapidly alternating movements. However, no limitations in coordination or voluntary exercise performance were apparent in CK-2066260-treated rats; rather, they showed better in vivo rotarod and treadmill running performance than vehicle-treated rats.

Although fatigue from high-intensity exercise is also associated with metabolic stress that causes decreased SR Ca\(^{2+}\) release, decreased myofibrillar Ca\(^{2+}\) sensitivity, and decreased myofibrillar force, these metabolic changes including metabolite clearance of inorganic phosphate ions and phosphocreatine re-synthesis are readily reversed within 5 min post-exercise. This implicates other factors being responsible for induction of PLFFD after high-intensity exercise. For instance, high-intensity contractions cause large increases in the production of reactive oxygen and nitrogen species within skeletal muscle, and these highly reactive molecules have been shown to induce long-lasting effects on SR Ca\(^{2+}\) release.

**FIGURE 5** Prolonged low-frequency force depression induced by repeated lengthening contractions is partially ameliorated by CK-2066260 superfusion. (A) Typical force recordings from the first and last (10th) 100 Hz tetanus involving an initial isometric contraction at optimal length with a 20% lengthening step given midway during the contractions (dashed blue line). Representative traces and mean values (±standard error of the mean, n = 5) of (B) 30 Hz and (C) 120 Hz force elicited in the unfatigued state (PRE), at 30 min of recovery (R30), and after an additional 5 min superfusion with 10 μM CK-2066260 (CK260). *Significantly different from value at PRE at P < 0.05.
and myofibrillar contractile function.\textsuperscript{20,55–57} Still, antioxidants have largely been unsuccessful in reversing PLFFD because submaximal force depends on a fine-tuned, and not fully characterized, redox balance where both severely reduced and oxidized states within skeletal muscle can depress contractile force.\textsuperscript{22,24,58} Here, we show that treatment with a FSTA effectively increases forces up to the unfatigued level during PLFFD induced by high-intensity contractions (see Figure 4), and this is achieved without any increase in SR Ca\textsuperscript{2+} release or restoration of redox-induced modifications involved in the development of this type of weakness.

During repeated eccentric contractions, the high forces produced during lengthening are known to induce mechanical damage to the myofibrillar contractile machinery, but the exact mechanisms underlying the decreased force-generating capacity are still uncertain.\textsuperscript{27,37,59,60} Although the force reduction after damaging eccentric contractions is larger at low than at high stimulation frequencies (i.e. PLFFD is present), force is also depressed at high stimulation frequencies, hence reflecting a decrease in the maximum force-generating capacity.\textsuperscript{19,27} Our present results show that while application of FSTA CK-2066260 effectively increases the force at low (30 Hz) stimulation, it is ineffective at (120 Hz) stimulation (see Figure 5). This latter finding is expected because increasing the myofibrillar Ca\textsuperscript{2+} sensitivity would not increase the force produced by maximally Ca\textsuperscript{2+}-activated myofilaments.

In conclusion, we here demonstrate that the FSTA, CK-2066260, effectively increases submaximal force in conditions with muscle weakness, and this force-potentiating effect is not restricted to a specific mechanism underlying the weakness. Thus, FSTAs have the potential to markedly improve physical performance in humans where everyday activities are limited by muscle weakness, premature fatigue, and exercise intolerance. To this date, the FSTAs tirasemtiv and reldesemtiv have been shown to amplify the skeletal muscle force response to nerve stimulation in healthy human subjects,\textsuperscript{51,62} and FSTAs merit further clinical trial investigation to better identify its potential to improve muscle function in conditions characterized by muscle weakness and fatigue.

Acknowledgements

The authors of this manuscript certify that they comply with the ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle.\textsuperscript{63}

Conflict of interest

D.T.H and F.I.M. are current employees of Cytokinetics, Inc. and were compensated financially for their work. The laboratory of H.W. received financial support from Cytokinetics, Inc.

Funding

The study was supported by grants from the Swedish Research Council (Vetenskapsrådet, H.W., 2018-02576) and the Swedish Research Council for Sport Science (A.J.C., FO2018-0019; H.W., P2019-0060).

Online supplementary material

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Figure S1. Schematic of the three experimental protocols. CK-2066260 (CK260), prolonged low-frequency force depression (PLFFD).

References

1. Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB et al., Sarcopenia: an undiagnosed condition in older adults. Current consensus definition, prevalence, etiology, and consequences. International Working Group on Sarcopenia. J Am Med Dir Assoc. 2011;12:249–256.
2. Ruiz JR, Sui X, Lobelo F, Morrow JR Jr, Jackson AW, Sjöström M, et al. Association between muscular strength and mortality in men: prospective cohort study. BMJ 2008;337:a3435.
3. Cooper R, Kuh D, Hardy R, Mortality Review Group, on behalf of the FALCon and HALCyon study teams. Objectively measured physical capability levels and mortality: systematic review and meta-analysis. BMJ 2010;341:c4467.
4. Moylan JS, Reid MB. Oxidative stress, chronic disease, and muscle wasting. Muscle Nerve 2007;35:411–429.
5. Westerblad H, Place N, Yamada T. Mechanisms of skeletal muscle weakness. Adv Exp Med Biol 2010;682:279–296.
6. Larsson L, Li X, Edström L, Eriksson LI, Zackriss H, Argentini C, et al. Acute quadriplegia and loss of muscle myosin in patients treated with nondepolarizing neuromuscular blocking agents and corticosteroids: mechanisms at the cellular and molecular levels. Crit Care Med 2000;28:34–45.
7. Acharyya S, Ladner KJ, Nelsen LL, Damrauer J, Reiser PJ, Swoap S, et al. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 2004;114:370–378.
8. Ochala J, Larsson L. Effects of a preferential myosin loss on Ca\textsuperscript{2+} activation of force generation in single human skeletal muscle fibres. Exp Physiol 2008;93:486–495.
9. Yamada T, Fedotovskaya O, Cheng AJ, Cornachione AS, Minozzo FC, Aulin C, et al. Nitrosative modifications of the Ca\textsuperscript{2+} release complex and actin underlie arthritis-induced muscle weakness. Ann Rheum Dis 2015;74:1907–1914.
10. Yamada T, Steinz MM, Kenne E, Lanner JT.
Muscle weakness in rheumatoid arthritis: the role of Ca²⁺ and free radical signaling.
*EbioMedicine* 2017;23:12–19.

11. Steinz MM, Persson M, Aresh B, Olsson K, Cheng AJ, Ahlstrand E, et al. Oxidative hotspot spots on actin promote skeletal muscle weakness in rheumatoid arthritis. *JCI Insight* 2019;4:e126347.

12. Andersson DC, Betzenhauser MJ, Reiken S, Meli AC, Umanaskaya A, Xie W, et al. Ryanodine receptor oxidation causes intra cellular calcium leak and muscle weakness in aging. *Cell Metab* 2011;14:196–207.

13. Ward OW, Reiken S, Marks AR, Marty J, Vassort G, Lacampagne A. Defects in ryanodine receptor calcium release in skeletal muscle from post-myocardial infarct rats. *FASEB J* 2003;17:1517–1519.

14. Andersson DC, Meli AC, Reiken S, Betzenhauser MJ, Umanaskaya A, Shiomi T, et al. Leaky ryanodine receptors in β-sarcoglycan deficient mice: a potential common defect in muscular dystrophy. *Skeletal Muscle*. 2012;2:1.9. https://doi.org/10.1186/2044-5040-2-9

15. Asomaning DC, Hänninen SL, Wredenberg A, Tavi P, Park CB, et al. Increased mitochondrial Ca²⁺ and decreased sarcoplasmic reticulum Ca²⁺ in mitochondrial myopathy. *Hum Mol Genet* 2009;18:278–288.

16. Waning DL, Mohammad KS, Reiken S, Xie W, Andersson DC, John S, et al. Excess TGF-β mediates muscle weakness associated with bone metastases in mice. *Nat Med* 2015;21:1262–1271.

17. Edwards RH, Hill DK, Jones DA, Merton PA. Fatigue of long duration in human skeletal muscle after exercise. *J Physiol* 1977;272:769–778.

18. Place N, Yamada T, Bruton JD, Westerblad H. Muscle fatigue: from observations in human quadriceps muscle. *Eur J Appl Physiol* 2010;110:1–15.

19. Skurvydas A, Mambetov K, Kamandulis S, Delaney V, Balanci D, Westerblad H. Mechanisms of force depression caused by different types of physical exercise studied by direct electrical stimulation of human quadriceps muscle. *Eur J Appl Physiol* 2016;116:2251–2224.

20. Bruton JD, Place N, Yamada T, Silva JP, Andrade FH, Dahldstedt AJ, et al. Reactive oxygen species and fatigue-induced prolonged low frequency depression in skeletal muscle fibres of rats, mice and *SD2* overexpressing mice. *J Physiol* 2008;586:175–184.

21. Westerblad H, Duty S, Allen DG. Intracellular calcium concentration during low-frequency fatigue in isolated single fibres of mouse skeletal muscle. *J Appl Physiol* 1993;75:382–388.

22. Cheng AJ, Bruton JD, Lanner JT, Westerblad H. Antioxidant treatments do not improve force recovery after fatiguing stimulation of mouse skeletal muscle fibres. *J Physiol* 2015;593:457–472.

23. Gandra PG, Shiah AA, Nogueira L, Hogan MC. A mitochondrial-targeted antioxidant improves myofilament Ca²⁺ sensitivity during prolonged low frequency force depression at low P0. *J Physiol* 2018;596:1079–1089.

24. Watanabe D, Albara C, Wada M. Treatment with EUK-134 improves sarcoplasmic reticulum Ca²⁺ release but not myofilibrar Ca²⁺ sensitivity after fatigue contraction of rat fat-twitch muscle. *Am J Physiol Regul Integr Comp Physiol* 2019;316:R543–R551.

25. Place N, Ivarsso N, Venckusas T, Neyroud D, Brazaitis M, Cheng AJ, et al. Ryanodine receptor fragmentation and sarcoplasmic reticulum Ca²⁺ leak after one session of high-intensity interval exercise. *Proc Natl Acad Sci U S A* 2015;112:15492–15497.

26. Martin V, Millet GY, Martin A, Deley G, Lattier G. Assessment of low-frequency fatigue with two methods of electrical stimulation. *J Appl Physiol* 2004;97:1923–1929.

27. Kamandulis S, de Souza Leite F, Hernandez A, Katz A, Brazaitis M, Bruton JD, et al. Prolonged force depression after mechanically demanding contractions is largely independent of Ca²⁺ and reactive oxygen species. *FASEB J* 2017;31:4809–4820.

28. Hwee DT, Kennedy AR, Hartman JJ, Ryan JS, Hamil FL, et al. The small-molecule fast skeletal troponin activator, CK-2127107, improves exercise tolerance in a rat model of heart failure. *J Pharmacol Exp Ther* 2015;353:159–168.

29. Hwee DT, Cheng AJ, Hartman JJ, Hinken AC, Lee K, Durham N, et al. The Ca²⁺-sensitizer CK-2066260 increases myofibrillar Ca²⁺ sensitivity and submaximal force selectively in fast skeletal muscle. *J Physiol* 2017;595:1657–1670.

30. Russell AJ, Hartman JJ, Hinken AC, Muci AR, Kawas R, Driscoll L, et al. Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuro muscular diseases. *Nat Med* 2012;18:452–455.

31. Cheng AJ, Hwee DT, Kim LH, Durham N, Yang HT, Hinken AC, et al. Fast skeletal muscle troponin activator CK-2066260 increases fatigue resilience by reducing the energetic cost of muscle contraction. *J Physiol* 2019;597:4615–4625.

32. Grimby L, Hannert J. Firing rate and recruitment order of toe extensor motor units in different modes of voluntary contraction. *J Physiol* 1977;264:865–879.

33. Hennig R, Lamó T. Firing patterns of motor units in normal rats. *Nature* 1985;314:164–166.

34. Cheng AJ, Westerblad H. Mechanical isolation, and measurement of force and myoplasmic free Ca²⁺ in fully intact single skeletal muscle fibers. *Nat Protoc* 2012;7:1763–1776.

35. Cheng AJ, Willis SJ, Zinner C, Chaillou T, Ivarsso N, Ørtenblad N, et al. Post-exercise recovery of contractile function and endurance in humans and mice is accelerated by housing and slowed by cooling skeletal muscle. *J Physiol* 2017;595:7413–7426.

36. Bruton JD, Lännergren J, Westerblad H. Effects of CO₂-induced acidification on the fatigue resistance of single mouse muscle fibers at 28°C. *J Appl Physiol* 1998;85:478–483.

37. Proske U, Morgan DL. Muscle damage from eccentric exercise: mechanism, mechanical signs, adaptation and clinical applications. *J Physiol* 2001;537:333–345.

38. Reid MB, Moylan JS. Beyond atrophy: re dox mechanisms of muscle dysfunction in chronic inflammatory disease. *J Physiol* 2011;589:2171–2179.

39. Powers SK, Lynch GS, Murphy KT, Reid MB, Zijdewind I. Disease-induced skeletal muscle atrophy and fatigue. *Med Sci Sports Exerc* 2016;48:2307–2319.

40. Booth FW, Roberts CK, Thfyault JP, Ruegsegger GN, Toedebusch RG. Role of in activity in chronic diseases: evolutionar in sight and pathophysiological mechanisms. *Physiol Rev* 2017;97:1351–1402.

41. Rolland Y, Calliswski S, Abellan Van Kan G, Morley JE, Mander M, Onder G, et al. Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. *J Nutr Health Aging* 2008;12:433–450.

42. Larsson L, Friedrich O. Critical illness myopathy (CIM) and ventilator-induced diaphragm muscle dysfunction (VIDD): acquired myopathies affecting contractile proteins. *Compr Physiol* 2016;7:105–112.

43. Bergström J, Hermansen L, Hultman E, Soltin B. Diet, muscle glycogen and physical performance. *Acta Physiol Scand* 1967;71:140–150.

44. Nielsen J, Holmberg HC, Schrøder HD, Soltin B, Ørtenblad N. Human skeletal muscle glycogen utilization in exhaustive exercise: role of subcellular localization and fibre type. *J Physiol* 2011;589:2871–2885.

45. Chin ER, Allen DG. Effects of reduced muscle glycogen concentration on force, Ca²⁺ release and contractile protein function in intact mouse skeletal muscle. *J Physiol* 1997;498:17–29.

46. Hølender I, Westerblad H, Katz A. Effects of glucose on contractile function, [Ca²⁺], and glycogen in isolated muscle mouse. *Am J Physiol Cell Physiol* 2002;282:C1306–C1312.

47. Ørtenblad N, Westerblad H, Nielsen J. Muscle glycogen stores and fatigue. *J Physiol* 2013;591:4405–4413.

48. Piehl K, Adolffsson S, Nazar K. Glycogen storage and glycogen synthetase activity in trained and untrained muscle of man. *Acta Physiol Scand* 1974;90:779–788.

49. Krstrup P, Ørtenblad N, Nielsen J, Nybo L, Gunnarsson TP, Iaia FM, et al. Maximal vol untary contraction force, FR function and glycogen resynthesis during the first 72 h after a high-level competitive soccer game. *J Appl Physiol* 2011;111:2987–2995.

50. Nielsen J, Cheng AJ, Ørtenblad N, Westerblad H. Subcellular distribution of glycogen and decreased tetanic Ca²⁺ in fatigued single intact mouse muscle fibres. *J Physiol* 2014;592:2003–2012.

51. Cheng AJ, Place N, Westerblad H. Molecular basis for exercise-induced fatigue: the...
importance of strictly controlled cellular Ca\textsuperscript{2+} handling. *Cold Spring Harb Perspect Med* 2018;8:a029710.

53. Bogdanis GC, Nevill ME, Boobis LH, Lakomy HK, Nevill AM. Recovery of power output and muscle metabolites following 30 s of maximal sprint cycling in man. *J Physiol* 1995;482:467–480.

54. Sakellariou GK, Jackson MJ, Vasilaki A. Redefining the major contributors to superoxide production in contracting skeletal muscle. The role of NAD(P)H oxidases. *Free Radic Res* 2014;48:12–29.

55. Andrade FH, Reid MB, Westerblad H. Contractile response of skeletal muscle to low peroxide concentrations: myofibrillar calcium sensitivity as a likely target for redox-modulation. *FASEB J* 2001;15:309–311.

56. Cheng AJ, Yamada T, Rassier D, Andersson DC, Westerblad H, Lanner JT. Reactive oxygen/nitrogen species and contractile function in skeletal muscle during fatigue and recovery. *J Physiol* 2016;594:5149–5160.

57. Lamb GD, Westerblad H. Acute effects of reactive oxygen and nitrogen species on the contractile function of skeletal muscle. *J Physiol* 2011;589:2119–2127.

58. Fridén J, Sjöström M, Ekblom B. Myofibrillar damage following intense eccentric exercise in man. *Int J Sports Med* 1983;4:170–176.

59. Cheng AJ, Yamada T, Rassier D, Andersson DC, Westerblad H, Lanner JT. Reactive oxygen/nitrogen species and contractile function in skeletal muscle during fatigue and recovery. *J Physiol* 2016;594:5149–5160.

61. Hansen R, Saikali KG, Chou W, Russell AJ, Chen MM, Vijayakumar V, et al. Tirasemtiv amplifies skeletal muscle response to nerve activation in humans. *Muscle Nerve* 2014;50:925–931.

62. Andrews JA, Miller TM, Vijayakumar V, Stoltz R, James JK, Meng L, et al. CK-2127107 amplifies skeletal muscle response to nerve activation in humans. *Muscle Nerve* 2018;57:729–734.

63. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2019. *J Cachexia Sarcopenia Muscle* 2019;10:1143–1145.